Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ATP150 + ATP152 + VSV-GP154 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ATP150 | ATP-150|ATP 150 | Limited information is currently available on ATP150 (Feb 2025). | ||
| ATP152 | ATP-152|ATP 152 | Limited information is currently available on ATP152, a putative therapeutic protein vaccine (May 2023). | ||
| VSV-GP154 | VSV GP154|VSVGP154 | VSV-GP154 is a vesicular stomatitis virus (VSV) viral vector-based cancer vaccine containing pancreatic adenocarcinoma patient-derived tumor-associated antigen peptides, which preferentially replicates in tumor cells expressing KRAS G12V or KRAS G12D, potentially resulting in tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05846516 | Phase I | ATP162 + Ezabenlimab + VSV-GP154 ATP150 + ATP152 + VSV-GP154 ATP150 + ATP152 + Ezabenlimab + VSV-GP154 | A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma (KISIMA-02) | Recruiting | USA | ESP | DEU | CHE | 0 |